Horizontes de la proteómica en el diagnóstico y el tratamiento de la enfermedad cardiovascular
- Antonio López Farré 1
- Juan González Armengol 2
- Petra J. Mateos-Cáceres 1
- Carlos Macaya 1
- 1 Unidad de Investigación Cardiovascular. Servicio de Cardiología. Instituto Cardiovascular. Hospital Clínico San Carlos. Madrid
- 2 Servicio de Urgencias. Hospital Clínico San Carlos. Madrid
ISSN: 0214-9168, 1578-1879
Année de publication: 2008
Volumen: 20
Número: 4
Pages: 164-172
Type: Article
D'autres publications dans: Clínica e investigación en arteriosclerosis
Résumé
Proteomics is a new technology, even being considered as a new science that can analyse the expression of many proteins at the same time in a single sample. Proteomics may help us to identify new biomarkers for use in the diagnosis and prognosis of cardiovascular diseases. Proteomic analysis is starting to produce results in the knowledge of cardiovascular diseases including, atherosclerosis, myocardial ischaemia and ventricular hypertrophy. One important application of proteomics is pharmacoproteomics, which attempts to identify biomarkers that may be able to predict the pharmacological response of a patient. Furthermore, we may be able to use pharmacoproteomics to identify variations in protein expression associated to a specific pharmacological treatment, which will help in understanding the class and pleiotropic action of drugs.